22 recruiting. 22 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Recruiting 22 |
| Phase 1 | 7 | Recruiting 7 |
Follow Large B-cell Lymphoma: new trials by email Literature Review of Large B-cell Lymphoma trials Research Report on Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma Leukapheresis, Lymphodepleting Chemotherapy - Large B-cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2026-03-17 | 2026-06-30 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study Glofitamab, PD-1 Inhibitor, Lenalidomide - Large B-cell Lymphoma, TP53 | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2025-09-01 | 2025-11-20 |
| A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T Tislelizumab, Zanubrutinib, Tislelizumab + Zanubrutinib - Large B-cell Lymphoma | Phase 2 | Recruiting | University Health Network, Toronto | 76 | 2025-06-04 | 2026-06-09 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym Tafasitamab, Lenalidomide - Large B-cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 28 | 2025-03-19 | 2026-04-03 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-10-28 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma Glofitamab, Polatuzumab vedotin, Obinutuzumab - Large B-cell Lymphoma | Phase 2 | Recruiting | University College, London | 99 | 2024-08-16 | 2024-12-24 |
| CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma Relma-cel - Non-Hodgkin Lymphoma, Large B-cell Lymphoma | Phase 2 | Recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 12 | 2024-08-15 | 2024-08-21 |
| A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | Malaghan Institute of Medical Research | 60 | 2024-07-12 | 2026-08-07 |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide - Large B-cell Lymphoma | Phase 2 | Recruiting | Allogene Therapeutics | 250 | 2024-06-18 | 2026-10-02 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL GFH009, Zanubrutinib - Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 51 | 2024-03-20 | 2025-08-12 |
| A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies ALETA-001 - Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 84 | 2024-02-07 | 2025-07-28 |
| Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Prednisone, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-01-05 | 2026-09-25 |
| Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-11-08 | 2026-03-31 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Lyell Immunopharma, Inc. | 270 | 2023-05-09 | 2026-08-25 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
Showing 20 of 22. Sign in to see all of them.
Lymphoma, Non-Hodgkin (9) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma (6) · Lymphoma, B-Cell (6) · Recurrence (6) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Burkitt Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Disease Attributes (1) · Immune System Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
Hemic and Lymphatic Diseases (16) · Immunoproliferative Disorders (16) · Lymphatic Diseases (16) · Lymphoproliferative Disorders (16) · Neoplasms by Histologic Type (16) · Immune System Diseases (15) · Neoplasms (15) · Lymphoma (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Disease Attributes (8) · Lymphoma, B-Cell (7) · Lymphoma, Non-Hodgkin (6) · Hematologic Diseases (4) · Leukemia, Lymphoid (4)
Cyclophosphamide (7) · fludarabine (4) · glofitamab (3) · obinutuzumab (3) · Lenalidomide (2) · Leukapheresis (2) · Prednisone (2) · Rituximab (2) · Vincristine (2) · fludarabine phosphate (2) · loncastuximab tesirine (2) · zanubrutinib (2) · Antibodies, Monoclonal (1) · Dexamethasone (1) · Doxorubicin (1)
M.D. Anderson Cancer Center (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Allogene Therapeutics (1) · AstraZeneca (1) · CRISPR Therapeutics AG (1) · Cancer Research UK (1) · Estrella Immunopharma, Inc. (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · KK Women's and Children's Hospital (1) · Lyell Immunopharma, Inc. (1) · Malaghan Institute of Medical Research (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Massachusetts General Hospital (1) · Shanghai Ming Ju Biotechnology Co., Ltd. (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (14) · Australia (4) · China (4) · United Kingdom (3) · Canada (2) · South Korea (2) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · New Zealand (1) · Singapore (1) · Spain (1)
Aloysius Ho, MD (1) · Dai Chihara, MD (1) · Dai Chihara, MD, PHD (1) · Frederick Locke, MD (1) · Huilai Zhang (1) · Jeremy Abramson, MD, MMSc (1) · John Kuruvilla, FRCPC (1) · Juan Alderuccio, MD (1) · Keshu Zhou, MD (1) · Matthew Frigault, MD (1) · Melanie Allen, M.Sc. (1) · Michael Jain, MD, PhD (1) · Paolo Strati, MD (1) · Pei Wang, PhD (1)